Opportunity analysis of an antibody-cleaving enzyme in oncology & autoimmune diseases

Challenge: A biopharmaceutical company with a focus on immunomodulatory compounds was looking to expand the application of its lead product in oncology, specifically, by adapting the product to...
Learn More

Indication selection assessment for clinical stage oncology small molecule

Challenge: A venture capital firm was interested in an independent indication selection strategic assessment of a clinical stage small molecule oncology asset they had invested in, based on the...
Learn More

Opportunity mapping in myelofibrosis for phase II product

Challenge: An inflammation and oncology-focused biotech company was looking to expand the clinical footprint of one of its phase II products. Our client was discussing the potential positioning of...
Learn More

Building Target Product Profiles and conducting rNPV valuations of lead development assets

Challenge: A clinical stage company developing small molecules to treat fibrotic diseases engaged Alacrita to quantify the value potential of their lead asset in idiopathic pulmonary fibrosis (IPF),...
Learn More

Opportunity mapping & indication strategy for company developing exosome-based therapies

Challenge: A clinical stage stem-cell company with its own proprietary cell lines had developed technologies to enable production of exosomes at a commercially relevant scale. The company asked...
Learn More

Validating two potential hormone replacement therapy products with KOLs

Challenge: A clinical-stage company developing novel transdermal patch technology asked us to validate two potential hormone replacement therapy products with KOLs. The main focus was to evaluate the...
Learn More

Oligo technology applications mapping

Challenge: A startup with a novel technology for enzymatic synthesis of dsDNA approached Alacrita to assess potential opportunities for the technology in the biopharma space. Hitherto the company had...
Learn More

LNP technology and competitive landscape

Challenge: A privately held biotech company using AI/machine learning/Big Data to develop novel LNPs and LNP formulations for particular payloads instead of using a traditional “trial and error”...
Learn More

Landscape Analysis of the Radiopharma Market

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...
Learn More

Assessment of TLR immunomodulators in oncology and HIV

Challenge:  A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...
Learn More

Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

Challenge: Our client was a leading UK research institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita...
Learn More

Opportunity map for 3D Printing Technology for medical products

Challenge: A university commercialization institute asked Alacrita to review its technology for 3D printed, customised silicone medical products. The main task was to determine the prospective value...
Learn More
1 2
Content not found